Document:

Exhibit 4.2

 

AMENDED AND RESTATED

AGREEMENT REGARDING REGISTRATION OF SHARES

 

This AMENDED AND RESTATED AGREEMENT REGARDING REGISTRATION OF SHARES (“Agreement”) is made as of August 4, 2004 by
and between NAVTEQ Corporation (“Company”)
and NavPart I B.V. (“Stockholder”).

 

WHEREAS, on April 20, 2004, the Company has filed a registration
statement on Form S-1 (as amended, “Registration
Statement”) with the Securities and Exchange Commission under the
Securities Act of 1933, as amended (“Act”),
to register the offer and sale of certain shares of the Company’s common stock,
$0.001 par value, held by Philips Consumer Electronic Services B.V. (“Philips”) pursuant to a firm commitment
underwritten public offering (“Offering”);
and

 

WHEREAS, the Stockholder has requested that the Company register the
offer and sale under the Act certain shares of the Company’s common stock it
holds (“Stockholder Shares”) by
including such shares in the Registration Statement; and

 

WHEREAS, the Company has indicated its willingness to include such
Stockholder Shares in the Registration Statement, and on May 17, 2004, the
Company and Stockholder entered into an Agreement Regarding Registration of
Shares (“Original Agreement”); and

 

WHEREAS, since the date of the Original Agreement certain events have
occurred that all parties agree require an amendment of the terms and
conditions specified in the Original Agreement;.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants
contained herein, the parties agree as follows:

 

1.                                       Agreement
to Register Shares.  Subject to the
conditions set forth herein, the Company agrees to use its commercially
reasonable efforts to register the Stockholder Shares by including such shares
in the Registration Statement.  The
number of Stockholder Shares to be registered will be determined through
consultation with Credit Suisse First Boston LLC and Merrill Lynch & Co.,
the Underwriters of the Offering.  Such
number of shares may be increased or decreased at any time prior to the
completion of the Offering in the sole discretion of the Underwriters.

 

2.                                       Conditions
to Company’s Obligation.  In
addition to the condition set forth in Section 5 below, the obligations of the
Company to include the Stockholder Shares in the Registration Statement are
expressly subject to the following conditions:

 

(a)                                  the
Stockholder shall become a party to the Underwriting Agreement between the
Company, the Underwriters, Philips and the Stockholder;

 

(b)                                 the
Stockholder cooperates with the Company and the Underwriters as requested by
the Company and/or Underwriters in connection with the Registration

 

 

Statement and
the Offering, including, without limitation, providing such information as is
requested by them for inclusion in the Registration Statement and executing such
agreements, acknowledgments and certificates as are customary in transactions
of this type;

 

(c)                                  Philips
consents to the inclusion of the Stockholder Shares in the Registration
Statement; and

 

(d)                                 the
Registration Statement is not withdrawn and/or the Offering is not completed
for any reason.

 

3.                                       Fees
and Expenses.  The Company shall be
responsible for the Securities and Exchange Commission, National Association of
Securities Dealers, Inc., New York Stock Exchange and “blue sky” law
registration, qualification and compliance fees and expenses in connection with
the registration of the Stockholder Shares. 
The Selling Stockholder shall be responsible for all underwriting
discounts, selling commissions and transfer taxes, if any, applicable to the
sale of the Stockholder Shares., and the fees and expenses of its counsel.

 

4.                                       No
Other Registration Rights.  The
Stockholder acknowledges and agrees that the Company’s agreement to register
the Stockholder Shares pursuant to this Agreement does not create any further
right of Stockholder to have any of its shares registered in any subsequent
registration of the offer and sale of Company securities under the Act (whether
in an offering by the Company or for the account of any Company
securityholder).  The Stockholder
further acknowledges and agrees that nothing in this Agreement is intended to
make the Stockholder a party to or confer upon such Stockholder any rights set
forth in that certain Registration Rights Agreement dated as of March 29, 2001
by and between the Company and Philips.

 

5.                                       Agreement
of Underwriters.  The obligations of
the Company and the rights of the Stockholder under this Agreement are
expressly conditioned on the consent and agreement of the Underwriters to
include the Stockholder Shares in the Offering.  In the event that the Underwriters determine, in their sole
discretion, not to include the Stockholder Shares in the Offering, the
Company’s obligations under this Agreement shall cease and be of no further
force or effect.

 

6.                                       Reasonable
Investigation.  In connection with
the preparation and filing of the Registration Statement and the completion of
the Offering, the Company will provide the Stockholder reasonable and customary
access to the Company’s books and records and such opportunities to discuss the
business of the Company with its officers as shall be reasonably necessary to
conduct a reasonable investigation within the meaning of the Act.

 

7.                                       Representations,
Warranties and Agreements of Stockholder. 
This Agreement has been duly authorized, executed and delivered by or on
behalf of Stockholder.  Stockholder has,
and at the closing of the Offering will have, valid title to the Stockholder
Shares free and clear of all security interests, claims, liens, equities or
other encumbrances and the

 

2

 

legal right
and power, and all authorization and approval required by law, to enter into
this Agreement and to sell, transfer and deliver the Stockholder Shares.

 

8.                                       Indemnification
and Contribution.

 

(a)                                  Indemnification by the Company. The
Company shall indemnify and hold harmless Stockholder, and its officers and
directors and each Person who controls Stockholder within the meaning of
Section 15 of the Act or Section 20 of the Securities Exchange Act of 1934 (the
“Exchange Act”) (each such person being sometimes referred to as an “Indemnified Person”) against any losses,
claims, damages or liabilities, joint or several, to which such Indemnified
Person may become subject under the Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon an untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, or any Prospectus contained therein,
or any amendment or supplement thereto, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, and
the Company hereby agrees to reimburse such Indemnified Person for any legal or
other expenses reasonably incurred by them in connection with investigating or
defending any such action or claim as such expenses are incurred; provided, however,
that the Company shall not be liable to any such Indemnified Person in any such
case to the extent that any such loss, claim, damage or liability arises out of
or is based upon an untrue statement or alleged untrue statement or omission or
alleged omission made in the Registration Statement or Prospectus, or amendment
or supplement, in reliance upon and in conformity with written information
furnished to the Company by Stockholder expressly for use therein.  For purposes of this Section 8, the term
“Person” means any individual, partnership, corporation or similar entity,
trust or unincorporated organization, and the term “Prospectus” means the
prospectus included in the Registration Statement, including any preliminary
prospectus, and any supplement thereto.

 

(b)                                 Indemnification by Stockholder.  Stockholder agrees to (i) indemnify and hold
harmless the Company, and its directors and officers who sign the Registration
Statement and each Person, if any, who controls the Company within the meaning
of either Section 15 of the Act or Section 20 of the Exchange Act, against any
losses, claims, damages or liabilities to which the Company or such other
persons may become subject, under the Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon an untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement or Prospectus, or any amendment or
supplement, or arise out of or are based upon the omission or alleged omission
to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, in each case to the extent, but
only to the extent, that such untrue statement or alleged untrue statement or
omission or alleged omission was made in reliance upon and in conformity with
written information furnished to the Company by Stockholder expressly for use
therein, and (ii) reimburse the Company for any legal or other expenses
reasonably incurred by the Company in connection with investigating or
defending any such action or claim as such expenses are incurred.

 

3

 

(c)                                  Notices of Claims, Etc.  Promptly after receipt by an indemnified
party under subsection (a) or (b) above of notice of the commencement of any
action, such indemnified party shall, if a claim in respect thereof is to be
made against an indemnifying party under this Section 8, notify such
indemnifying party in writing of the commencement thereof; but the omission so
to notify the indemnifying party shall not relieve it from any liability which
it may have to any indemnified party otherwise than under this Section 8. In
case any such action shall be brought against any indemnified party and it
shall notify an indemnifying party of the commencement thereof, such
indemnifying party shall be entitled to participate therein and, to the extent
that it shall wish, jointly with any other indemnifying party similarly
notified, to assume the defense thereof, with counsel reasonably satisfactory
to such indemnified party (who shall not, except with the consent of the
indemnified party, be counsel to the indemnifying party), and, after notice
from the indemnifying party to such indemnified party of its election so to
assume the defense thereof, such indemnifying party shall not be liable to such
indemnified party under this Section 8 for any legal expenses of other counsel
or any other expenses, in each case subsequently incurred by such indemnified
party, in connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the written consent of the
indemnified party, effect the settlement or compromise of, or consent to the
entry of any judgment with respect to, any pending or threatened action or
claim in respect of which indemnification or contribution may be sought
hereunder (whether or not the indemnified party is an actual or potential party
to such action or claim) unless such settlement, compromise or judgment (i)
includes an unconditional release of the indemnified party from all liability
arising out of such action or claim and (ii) does not include a statement as
to, or an admission of, fault, culpability or a failure to act, by or on behalf
of any indemnified party.

 

(d)                                 Contribution. If the indemnification
provided for in this Section 8 is unavailable to or insufficient to hold
harmless an indemnified party under subsection (a) or (b) above in respect of
any losses, claims, damages or liabilities (or actions in respect thereof)
referred to therein, then each indemnifying party shall contribute to the
amount paid or payable by such indemnified party as a result of such losses,
claims, damages or liabilities (or actions in respect thereof) in such
proportion as is appropriate to reflect the relative fault of the indemnifying
party and the indemnified party in connection with the statements or omissions
which resulted in such losses, claims, damages or liabilities (or actions in
respect thereof), as well as any other relevant equitable considerations. The
relative fault of such indemnifying party and indemnified party shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or omission or alleged omission to state a
material fact relates to information supplied by such indemnifying party or by
such indemnified party, and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The amount paid or payable by an indemnified party as a result of the losses,
claims, damages or liabilities (or actions in respect thereof) referred to
above shall be deemed to include any legal or other fees or expenses reasonably
incurred by such indemnified party in connection with investigating or
defending any such action or claim to the extent such fees or expenses were
incurred prior to an indemnifying party’s election to

 

4

 

assume the
defense of such action or claim. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.

 

(e)                                  Limitation.  Notwithstanding any other provision of this Section 8, in no
event will Stockholder be required to undertake liability to any Person under
this Section 8 for any amounts in excess of the dollar amount of the proceeds
to be received by Stockholder from the sale of Stockholder Shares in the Offering
(after deducting any fees, discounts and commissions applicable thereto).

 

(f)                                    Non-Exclusive Remedy. The obligations of
the Company under this Section 8 shall be in addition to any liability which
the Company may otherwise have to any Indemnified Person and the obligations of
any Indemnified Person under this Section 8 shall be in addition to any
liability which such Indemnified Person may otherwise have to the Company.  The remedies provided in this Section 8 are
not exclusive and shall not limit any rights or remedies which may otherwise be
available to an indemnified party at law or in equity.

 

9.                                       Non-Transferability.  The rights and obligations of the
Stockholder under this Agreement may not be transferred or assigned without the
written agreement of the Company.

 

10.                                 Governing
Law.  This Agreement and the rights
and obligations of the parties hereto shall be governed by and construed in
accordance with the laws of the state of Delaware, but not including the choice
of law rules thereof.

 

11.                                 Entire
Agreement.  This Agreement
constitutes the full and entire understanding and agreement of the parties with
regard to the subject matters described herein and supersedes and any and all
prior agreements and understandings between the parties with regard to the
subject matters described herein.  This
Agreement may be amended or modified only by written agreement of the parties.

 

12.                                 Execution
in Counterparts.  This Agreement may
be executed in any number of counterparts, each of which shall be an original,
but all of which together shall constitute one instrument.

 

[REMAINDER OF PAGE INTENTIONALLY BLANK - SIGNATURE PAGE FOLLOWS]

 

5

 

[signature page - Agreement Regarding Registration Of Shares]

 

IN WITNESS WHEREOF,  the parties have executed this Agreement as of the date first set
forth above.

 

	
   

  	
  COMPANY:

  
	
   

  	
   

  
	
   

  	
  NAVTEQ
  Corporation

  
	
   

  	
   

  
	
   

  	
  By:

  	
    /s/
  Lawrence M. Kaplan

  	
   

  
	
   

  	
   

  	
  Lawrence M.
  Kaplan

  
	
   

  	
   

  	
  Vice
  President and General Counsel

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  STOCKHOLDER:

  
	
   

  	
   

  
	
   

  	
  NavPart I
  B.V.

  
	
   

  	
   

  
	
   

  	
  By:

  	
    /s/
  Dirk-Jan van Ommeren

  	
   

  
	
   

  	
  Name:

  	
  Dirk-Jan van
  Ommeren

  
	
   

  	
  Title:

  	
  Director

  
						

 

6Exhibit 10.1

 

	
  

  	
  ADDENDUM to Technology Development

  Agreement and License Agreement

  

 

 

Parties:

 

Technology
Foundation STW, having its office at Utrecht, Van
Vollenhovenlaan 661 (3527 JP) The Netherlands, hereinafter referred to as
“STW”, legally represented by Dr. J.W. Maas, acting in its own name and;

 

Twente
University, having its office in the Netherlands at Enschede, at
the Drienerlolaan 5, (NL-7522 NB) Enschede, hereinafter referred to as
“INSTITUTION”, legally represented by P. Fij, director of the Faculty Science
and Technology;

 

and

 

IMMUNICON
CORPORATION, a Delaware corporation having offices at 3401 Masons
Mill Road, Huntingdon Valley, Pennsylvania 19006 (215)938 0437 fax, hereinafter
referred to as “IMMUNICON”; and

 

IMMUNIVEST
CORPORATION, a Delaware corporation having offices at Suite 1300,
1105 North market Street, P.O. Box 8985, Wilmington, Delaware 19899-8985,
hereinafter referred to as “IMMUNIVEST”

 

WHEREAS:

 

•                                          INSTITUTION,
more specifically the Faculty of Applied Physics, is carrying out a research
program subsidized by STW under supervision of prof. dr.ir. J. Greve, with the
title “Aids in Africa: affordable HIV staging”, further described in research
proposal with STW number: TGT.6146, known between parties, hereinafter referred
to as “the Research Project”;

 

•                                          the aim of
the Research Project is to develop a product for the detection and/or
monitoring of Acquired Immune Deficiency Syndrome or other conditions for use
solely in the countries of the African continent, within the definition of what
is hereinafter defined as the “Product”;

 

•                                          the
Research Project takes place with financial support from STW and according to
the conditions for this support STW and INSTITUTION are together the owners of
all results, including intellectual property rights, generated within the
Research Project;

 

1

 

•                                          The
Research Project is focussing on the development of a simple diagnostic tool at
low cost application for testing HIV and AIDS pro-/regression and with the goal
of a further optimized form of the IMMUNICON instrument “Easy Count 3.0”;

 

•                                          IMMUNICON
owns all proprietary rights in and to the Easy Count 3.0 instrument and with
respect thereto has contributed to the research prior to the start of the
Research Project;

 

•                                          INSTITUTION
and both IMMUNICON and IMMUNIVEST have concluded a technology development
agreement and a license agreement on April the 25 th 1997, of which copies
are attached to this agreement as Annex 1, and will be referred to hereinafter
as the “Complete License Agreement”;

 

•                                          the
Complete License Agreement is covering the so called Cytodisk Technology as
developed by the Institution and the granting of a license to processes,
products and technology to IMMUNIVEST;

 

•                                          IMMUNIVEST
has applied for several patent applications resulting from the Cytodisk
Technology that can be useful in the application of the results of the Research
Project. All the intellectual property rights to the expected results generated
in the Research Project are the subject matter of the Complete License
Agreement and shall be used in the further development of the Easy Count 3.0;

 

•                                          IMMUNIVEST
is interested in the results of the Research Project in order to commercially
apply them, through its affiliated entity IMMUNICON, in a Product and other
products and wishes to obtain the right to the exclusive use of such results;

 

•                                          IMMUNIVEST,
through its affiliate IMMUNICON,  is
interested in cooperation with STW and INSTITUTION regarding the Research
Project and is willing to contribute to the Research Project;

 

•                                          Parties
have decided to conclude an addendum to the Complete License Agreement to set
forth the rights the rights and obligations/conditions for the transfer of
intellectual property rights as described above related to the results
generated in the Research Project;

 

•                                          STW and
INSTITUTION are willing to assign such intellectual property rights to
IMMUNIVEST in order to enable the INSTITUTION to comply with the Complete
License Agreement regarding the results generated in the Research Project;

 

2

 

•                                          IMMUNIVEST
is willing to contribute to the Research Project and to pay a royalty for the
use of the results generated in the Research Project.

 

AGREE
AS FOLLOWS:

 

Definitions

Research Project: the
research program subsidized by STW under supervision of prof. dr.ir. J. Greve,
with the title “Aids in Africa: affordable HIV staging”, further described in
research proposal with STW number: TGT.6146

 

The Complete License
Agreement:     The Technology
Development Agreement between IMMUNICON and INSTITUTION and the License
Agreement between IMMUNIVEST and INSTITUTION, both concluded with the
INSTITUTION on April the 25 Th 1997,

 

Product:                                               The
optimized form of the IMMUNICON instrument Easy Count 3.0 which uses the
results of the Research project. The Easy Count 3.0 or any version of that
instrument which does not include any improvements based on the results of the
Research project shall not be considered a “Product” as defined herein.

 

Field:                                                                 all
methods, apparatus, products and services for analyzing magnetically selected
and aligned particles similar to cells, cell fragments, viruses, bacteria, and
synthetic materials and capture agents.

 

Net
Sales Price:     shall have the same
meaning as in the Complete License Agreement.

 

Article 1
– Relation to the Complete License Agreement

 

(1)                                  STW and
INSTITUTION hereby assign all their rights to the results of the Research
Project, including possible patent (applications) and all other intellectual property
rights related thereto (hereinafter “Intellectual Property”), within the Field
to IMMUNIVEST, subject to the provisions of this Addendum to the Complete
License Agreement. STW agrees to execute, at no cost to IMMUNIVEST, any
assignments or other documents necessary to vest title in the Intellectual
Property in IMMUNIVEST.

 

3

 

(2)                                  Concerning
the Research Project and this Addendum STW represents the INSTITUTION at law or
otherwise on the matter of intellectual property rights to the results of the
Research Project, subject to any terms of the Complete License Agreement
requiring assignment of inventions and provided that the Complete License
Agreement is still in force and is actually enforced fully by the INSTITUTION
or any patent (applications) resulting from the Research Results are still
valid.

 

(3)                                  IMMUNIVEST
hereby grants STW and INSTITUTION a non-exclusive license, without the right to
grant sublicenses, to practice the Research Results, including possible patent
(applications) solely for educational and research purposes and for no
commercial purpose.

 

(4)                                  IMMUNIVEST
will be entitled to participate in the User Committee for this Research, which
will be established by STW. This User Committee will meet at least once a year.
IMMUNIVEST has the power of veto to the admittance of other participants to the
User Committee.

 

(5)                                  STW and
INSTITUTION shall inform IMMUNIVEST regularly of the progress of the research,
including the research results, and shall disclose in detail to IMMUNICON any
inventions related thereto at least ninety (90) days prior to any public
disclosure thereof, on terms to be agreed upon in good faith between Parties.

 

(6)                                  All of the
rights and obligations established under this Agreement shall vest in any party
succeeding to the interest in this Agreement

 

Article 2
- Contribution to the Research Project and payment of royalty

 

(1)                                  In
consideration for the Agreement of IMMUNICON and IMMUNIVEST to the terms and
conditions of this Agreement, STW shall finance the Research Project with an
amount of 897.000, — euro and the INSTITUTION provides the Research Project
with the necessary infrastructure, guidance and overhead.

 

4

 

(2)                                  In
consideration for the financial support of STW and the support of the
INSTITUTION to the Research Project, IMMUNICON and IMMUNIVEST have supported
and will support the Research Project with personnel and materials amounting up
to 390,000 euro.

 

(3)                                  In
consideration for the right to use the results generated in the Research
Project, granted to IMMUNIVEST by way of article 1 in combination with the
Complete License Agreement, IMMUNIVEST shall owe and pay to STW a royalty of
2.5% (two and a half percent) of the Net Sales Price of Products sold within
the Field. The obligation to pay the royalty has effect as of the year in which
the first Product based on the results of the Research Project is sold.

 

(4)                                  In case
IMMUNICON or IMMUNIVEST can demonstrate that the Product is sold at production
cost price in resource poor-countries, or to the World Health Organisation
(WHO) or to any Non-Governmental Agency for example for the purpose of
affordable HIV staging or other purpose, the royalty will not be applicable.

 

(5)                                  IMMUNIVEST
shall send to STW in the month March of each year a report stating the
amount of Products within the Field actually sold in the foregoing year and the
Net Sales Price for these products. The reports on the amount of Products sold
shall include information about the production cost price and price on these
Products. STW shall send to IMMUNIVEST an invoice for the amounts due under
sub-paragraph 2 hereinabove in the month April of each calendar year.
IMMUNIVEST shall pay this invoice within 30 days after the invoice date.

 

(6)                                  STW is
entitled to have the above mentioned royalty statement verified by an
independent accountant at STW’s expense, no more often than once per year
during the term of this Agreement. In case the conclusions of the latter
deviate by more than 5% from the statement of IMMUNIVEST to the disadvantage of
STW, the costs of such verification shall be born by IMMUNIVEST. STW as the
accountant shall keep the statement strictly confidential

 

(7)                                  All
remunerations mentioned in this article are excluding VAT.

 

(8)                                  IMMUNIVEST
declares that they will assume an obligation to perform to the best of one’s
ability to produce any Products based on the results on the Research Project in
the Netherlands.

 

5

 

Article 3
- Reports, publications and secrecy

 

(1)                                  In
addition to the Complete License agreement IMMUNIVEST shall inform STW of any
and all patent applications, and the consequent patent maintenance of such
patent applications, which are filed in the name of IMMUNIVEST and relating to
the

(2)                                  results
generated in the Research Project, as soon as such information becomes
available to IMMUNIVEST.

 

(3)                                  In
addition to its obligations under the Complete License Agreement, each Party
hereto shall send to the others a copy of any intended scientific publication
by such Party whenever it is ready for submission for publication but in any
event at least ninety (90) days before the intended publication date in order
to allow time for the submission for patent applications on the subject matter
of such publication as may be appropriate prior to such publication date.

 

Article 4
- Miscellaneous

 

(1)                                 Liability

STW and INSTITUTION will carry out the Research
Project with care and diligence. STW and INSTITUTION however do not guarantee
that the expected results will be reached, nor that the results are fit for a
purpose, nor that the results of the research do not infringe rights of third
parties nor that patent applications will result in granted patents.

 

(2)                                 Non-transferability

This agreement, including all rights and
obligations, shall not be transferable by either Party without the written
consent of the other Party.

 

(3)                                 Termination

Both parties are entitled to terminate this
agreement in the event that the other Party violates any of the convenants or
obligations contained in this Agreement and such default continues unremedied
for a period of 30 (thirty) days after written notice thereof to this Party by
the first Party.

 

(4)                                 Applicable
law

This Agreement shall be governed by the Laws of
the Netherlands.

 

6

 

(5)                                 Disputes

Any dispute relating to the interpretation or
application of this Agreement shall, unless amicably settled, be subject to
mediation according to the modalities of the Dutch Mediation Institute
Foundation. In the event of failure of the latter within 6 months, the dispute
shall be settled by arbitration according to the rules of the Dutch Arbitration
Institute or with the rules of arbitration of the International Chamber of
Commerce. The parties shall accept the arbitral award as final.

(6)                                 Conflict

In the event of contrariety between the
contents of the Complete License Agreement and this Addendum, the contents of
the latter shall prevail.

 

Article 5     Term and
termination

 

(1)                                  This
Agreement shall come into force when duly signed by both Parties and shall
continue in full force and effect until the Complete License Agreement is
terminated or expires, or until any possible patent(s) resulting from the Research
Project expire or for ten years after the year in which the first Product is
sold, whichever is the longest period, subject to paragraph 2 and 3 hereunder.

 

(2)                                  This
agreement ends by operation of law when IMMUNICON or IMMUNIVEST goes into
liquidation or is granted a (temporary) suspension of payment.

 

(3)                                  Article 4
shall survive this agreement. In the event of termination of this Agreement by
IMMUNICON or IMMUNIVEST prior to the expiration of this Agreement except for
material breach by INSTITUTION or STW under Article 4 (3), or by operation
of law, IMMUNICON or IMMUNIVEST shall not be entitled to use or apply any
results including Intellectual property rights of the Research Project.

 

7

 

	
  Drawn in threefold and signed:

  	
   

  
	
   

  	
   

  
	
  Technology Foundation STW,

  	
  Twente University

  
	
  Utrecht, this 16th day of June,
  2004

  	
  Enschede, this15th day of June,
  2004.

  
	
   

  	
   

  
	
  /s/ J. W. MASS

  	
   

  	
  /s/ W.H. FIJ,

  	
   

  
	
  Dr. J.W. Maas, director

  	
  W.H. Fij, Director of the Faculty `

  
	
   

  	
  Science and Technology

  
	
   

  	
   

  
	
  IMMUNICON CORPORATION

  	
  IMMUNIVEST CORPORATION

  
	
  Huntingdon Valley, Pennsylvania

  	
  Wilmington, Delaware,

  
	
  this 11th day of June, 2004

  	
  this 11th day of June, 2004

  
	
   

  	
   

  
	
  /s/ EDWARD L ERICKSON

  	
   

  	
  /s/ JAMES L WILCOX

  	
   

  
	
  Edward L. Erickson, Chairman, President

  	
  James L. Wilcox, President

  
	
  & CEO

  	
   

  
						

 

8

 

ANNEX 1: Complete License Agreement (Twente
University and IMMUNIVEST CORPORATION)

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]